Tick Bite & TBE Protection
Tick-bite
Tick Bite & TBE Protection
Discover How to Help Stay Protected From Tick-Borne Encephalitis
There’s no cure for TBE, but it may be prevented.1,2
TBE is a rare viral infection for which there is no cure.1 Nor is there specific treatment for TBE, only
​​​​​​​management of symptoms.The World Health Organization (WHO) recommends TicoVac™ as an effective 
method against the contraction of the TBE virus while traveling to endemic countries throughout Europe 
and Asia.3
Most people infected with the TBE virus will not experience symptoms.4 But, if they do, the symptoms usually appear in two phases.5
Phase 01
People experience flu-like symptoms, including muscle pain, headache, fatigue, and a high temperature.5
Some patients
may appear
asymptomatic for
2-10 days
following Phase 015
Phase 02
Only some people experience the second phase, with more serious symptoms similar to other causes of inflammation of the brain and spine or meningitis.5 These symptoms may include a high fever, headache, nausea, vomiting, and vertigo.5
30-60%
suffering from severe 
disease develop 
​​​​​​​long-term consequences.6
Help Protect Yourself
If you are traveling to a country* that is affected by TBE, following a few simple steps can help reduce the chances of being bitten by a tick.1,5,7,8
Use the following protection and prevention methods to minimize your risk7:
  1. Avoid heavily tick-infested areas of forest and woodland from spring until fall, where possible.
  2. Wear light-colored clothing including long-sleeved tops and long trousers tucked into socks.8
  3. Use effective insect repellent and tick repellent.8
  4. Check your body for ticks regularly.
  5. Remove ticks as soon as possible by using a pair of fine-tipped tweezers
Vaccination is an effective preventative method for TBE.2 TicoVacTM may be available for people traveling to endemic countries and will have extensive exposure to ticks based on their planned outdoor activities and itinerary.
​​​​​​​Talk to your healthcare provider or a pharmacist about tick bite treatment and the importance of getting vaccinated with TicoVac.

LEARN MORE ABOUT TICOVAC™

* Albania, Austria, Belarus, Bosnia and Herzegovina, China, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Japan, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Mongolia, Netherlands, Norway, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, South Korea, Sweden, Switzerland, Ukraine.1,5
find a ticovacfind a ticovac
Find TicoVac™ 
​​​​​​​
Near You
The best place to get international travel health information specific to you and your travel plans is to contact your healthcare provider or pharmacist.

FIND TICOVAC™

References
  1. Dobler G, Erber W, Bröker M, Schmitt HJ, eds. The TBE Book. 4th ed. Global Health Press; 2021.
  2. TicoVac™ (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.
  3. World Health Organization Regional Office for Europe & European Center for Disease Prevention and Control. Tick-borne 
    encephalitis in Europe. Accessed February 24, 2022. https://www.euro.who.int/en/about-us/whd/past-themes-of-world-health-day/2014-vector-borne-diseases/fact-sheets-world-health-day-2014-vector-borne-diseases/fact-sheet-tick-borne-encephalitis-in-europe.
  4. Fischer M, Gould CV, Rollin PE. Tickborne Encephalitis. Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2017. Chap 4. Accessed February 9, 2022. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/tickborne-encephalitis.
  5. Kaiser R. Tick-borne encephalitis. Infect Dis Clin North Am. 2008;22(3):561-575. doi:10.1016/j.idc.2008.03.013
  6.  Centers for Disease Control and Prevention. Tick-borne encephalitis (TBE) Factsheet. Accessed February 24, 2022. https://
    www.cdc.gov/vhf/tbe/resources/TBE-FactSheet.pdf
    .
  7. Travel Health Pro. Diseases in Brief. Tick-borne encephalitis. Accessed February 24, 2022. https://travelhealthpro.org.uk/disease/173/
    tick-borne-encephalitis
    .
  8. Travel Health Pro. Insect and tick bite avoidance. Accessed February 24, 2022. https://travelhealthpro.org.uk/factsheet/38/insect-and-tick-bite-avoidance.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™. 
  • TicoVac™ may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
Indication

TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™. 
  • TicoVac™ may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
Indication

TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries.

The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

  • © 2022 Pfizer Inc.
  • All rights reserved.
  • Pfizer Inc. PO Box 29387, Mission, KS 66201
  • May 2022
  • PP-TCV-USA-0043
  • PP-TCV-USA-0043
  • PP-TCV-USA-0043